10/27/04

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612rxd

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	4	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	5	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	6	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	7	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	8	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	9	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	10	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	11	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	12	SEP 27	STANDARDS will no longer be available on STN
NEWS	13	SEP 27	SWETSCAN will no longer be available on STN

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:06:11 ON 27 OCT 2004

=> file registry

10/690738

10/27/04

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:06:20 ON 27 OCT 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 OCT 2004 HIGHEST RN 769912-90-5
DICTIONARY FILE UPDATES: 26 OCT 2004 HIGHEST RN 769912-90-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10690738.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 18:06:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7296 TO ITERATE

13.7% PROCESSED 1000 ITERATIONS 0 ANSWERS

```
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       140800 TO   151040
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 18:06:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 145959 TO ITERATE

100.0% PROCESSED  145959 ITERATIONS                          141 ANSWERS
SEARCH TIME: 00.00.03

L3          141 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             155.42     155.63

FILE 'CAPLUS' ENTERED AT 18:06:46 ON 27 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Oct 2004  VOL 141 ISS 18
FILE LAST UPDATED: 26 Oct 2004  (20041026/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4            12 L3

=> d abs bib fhitstr 1-12

L4   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2004 ACS on STN
GI
```



I

AB The invention discloses inhibition of viruses, e.g., HIV using quinolones and compds. related to quinolones with formula I [R1, R2, R3, R4 = H, (un)substituted alkyl,cycloalkyl,heteroalkyl,aryl,heteroaryl, NO2,CN and halogen, etc.; R5 = H, (un)substituted alkyl, cycloalkyl,heteroalkyl,aryl,heteroaryl,CN etc.; R6 = H, (un)substituted alkyl, aryl, heteroaryl; R7 = H, (un)substituted alkyl, heteroalkyl; and n = 1 - 4]. The invention further discloses methods for identifying and using agents, including small mol. chemical compns. that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS. Preparation of compds. of the invention is described.

AN 2004:370956 CAPLUS
DN 140:386005

TI Quinolones with anti-HIV activity, and preparation thereof

IN He, Yun; Ellis, David Archer; Anaclerio, Beth Marie; Kuhen, Kelli L.; Wu, Baogen; Jiang, Tao
PA IRM LLC, Bermuda

SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004037853	A2	20040506	WO 2003-US33528	20031021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004152719	A1	20040805	US 2003-690738	20031021
PRAI US 2002-420163P	P	20021021		

OS MARPAT 140:386005

IT **685539-93-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinolones with anti-HIV activity, and preparation thereof)

RN 685539-93-9 CAPLUS
CN 1aH-Cyclopropa[c]quinoline-1a-carboxylic acid, 6-chloro-7b-ethyl-1,2,3,7b-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AB A composition for modulating cholinergic function in a mammal comprises a nicotinic receptor partial agonist (NRPA) in combination with an anti-emetic/anti-nausea agent and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amts. that render the composition effective modulating cholinergic function or in the treatment of various disorders or conditions selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alc., benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compns. is also disclosed.

AN 2003:23533 CAPLUS

DN 138:83396

TI Pharmaceutical composition and method of modulating cholinergic function in a mammal

IN Coe, Jotham W.; Sands, Steven B.

PA Pfizer Inc., USA

SO U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003008892	A1	20030109	US 2002-105605	20020325
	WO 2003005998	A2	20030123	WO 2002-IB1767	20020521
	WO 2003005998	A3	20030530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,

GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	NZ 529607	A	20031219	NZ 2002-529607	20020521
	EP 1404320	A2	20040407	EP 2002-727942	20020521
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004167200	A1	20040826	US 2004-783790	20040220
PRAI	US 2001-303957P	P	20010709		
	US 2002-105605	A1	20020325		
	WO 2002-IB1767	W	20020521		

IT **483306-36-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing nicotinic receptor partial agonist in combination with antiemetic for modulating cholinergic function)
RN 483306-36-1 CAPLUS
CN 2H-Cyclopropa[c]quinolin-2-one, 5-[[(6-ethyl-2-phenyl-3-piperidinyl)amino]methyl]-1,1a,3,7b-tetrahydro-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a 5HT1D receptor antagonist. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT1D receptor antagonist.
AN 2002:183754 CAPLUS
DN 136:226804
TI Combination, for treating depression and anxiety, containing a 5HT1D receptor antagonist and a CNS penetrant NK-1 receptor antagonist
IN Schmidt, Christopher Joseph; Sobolov-Jaynes, Susan Beth
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1186318	A2	20020313	EP 2001-307220	20010824
	EP 1186318	A3	20030326		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2002049211	A1	20020425	US 2001-867357	20010529
	JP 2002121153	A2	20020423	JP 2001-264226	20010831
	BR 2001003913	A	20020521	BR 2001-3913	20010906
PRAI	US 2000-230257P	P	20000906		

OS MARPAT 136:226804
IT **368832-27-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination, for treating depression and anxiety, containing a 5HT1D receptor antagonist and a CNS penetrant NK-1 receptor antagonist)
RN 368832-27-3 CAPLUS
CN 2H-Cyclopropa[c]quinolin-2-one, 1,1a,3,7b-tetrahydro-6-methoxy-3-methyl-5-[[[(2R,3R)-2-phenyl-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB Title compds. I [Q = C:NH, C:CH2, C:S, C:O, SO, SO2; A = CH, CH2, C(alkyl), CH(alkyl), C(CF3), or CH(CF3) with the proviso that when B is present, A = CH, C(alkyl), or C(CF3); B = absent, CH2, or ethylene; Y, Z =

N, CH, provided that both are not N; G = NH(CH2)q, S(CH2)q, O(CH2)q; q = 0-1 with the proviso that when q = 0, G = NH2, SH, OH; W = 1-3 carbon linking group, including spiro assemblies; p = 0-2; R3 = H, acyl, carboxy, Ph, heterocyclyl, alkyl, etc.; R1, R2, R11-13 = H, alkyl, etc., or R12-13 together with the carbon atoms to which they are attached form a 5- or 6-membered heterocyclic ring, etc.; R4 = Ph, pyridyl, thienyl, etc.; R5-8 = H, alkyl, S(O)1-2-alkyl, S(O)1-2-aryl, alkoxy, halo, Ph, etc.] were prepared Approx. 100 synthetic examples and over 100 precursor prepns. were provided. For instance, 4-aminophenol was acylated with 3-chloropropionyl chloride (CH2Cl2, H2O, NaHCO3, room temperature, 4 h) and the product treated with AlCl3 at 210°C for 10 min effecting cyclization to the hydroxy quinolone intermediate. The intermediate was O-methylated (acetone, Me2SO4, K2CO3, room temperature, 16 h) and formylated in the 7 position (CH2Cl2, AlCl3, Cl2CHOMe) to give 7-formyl-6-methoxy-1H-1,2,3,4-tetrahydroquinolin-2-one. Reductive alkylation of the quinolone with (2S,3S)-3-amino-2-phenylpiperidine (a. PhMe, 3Å mol. sieves; b. dichloroethane, NaHB(OAc)3, room temperature, 16 h) yielded II. Compds. I are NK-1 receptor antagonists, i.e., substance P receptor antagonists. At least one stereoisomer of the example compds. had a binding affinity, as measured by Ki, of at least 600 nM. I are used in the treatment and prevention of a wide variety of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, etc.

AN 2001:762988 CAPLUS
DN 135:331346
TI Synthesis of benzoamide piperidine containing compounds as substance P antagonists
IN Arnold, Eric Platt; Chappie, Thomas Allen; Huang, Jianhua; Humphrey, John Michael; Nagel, Arthur Adam; O'Neill, Brian Thomas; Sobolov-Jaynes, Susan Beth; Vincent, Lawrence Albert
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 209 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077100	A2	20011018	WO 2001-IB629	20010406
	WO 2001077100	A3	20020307		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003087925	A1	20030508	US 2001-811218	20010316
	EP 1272484	A2	20030108	EP 2001-919702	20010406
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009936	A	20030506	BR 2001-9936	20010406
	JP 2004501072	T2	20040115	JP 2001-575573	20010406
	EE 200200588	A	20040415	EE 2002-588	20010406
	NZ 521346	A	20040730	NZ 2001-521346	20010406
	BG 107135	A	20030630	BG 2002-107135	20020923
	ZA 2002008072	A	20031008	ZA 2002-8072	20021008

	NO 2002004874	A	20021118	NO 2002-4874	20021009
PRAI	US 2000-195922P	P	20000410		
	US 2000-212922P	P	20000620		
	WO 2001-IB629	W	20010406		

OS MARPAT 135:331346

IT **368832-27-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; synthesis of benzoamide piperidine containing compds. as substance P antagonists)

RN 368832-27-3 CAPLUS

CN 2H-Cyclopropa[c]quinolin-2-one, 1,1a,3,7b-tetrahydro-6-methoxy-3-methyl-5-[[[(2R,3R)-2-phenyl-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Bicyclic and pentacyclic lactams I (R = Ph, 1-naphthyl; n = 1, 2, 7) and II (n = 1, 2) were prepared by thermal cyclization of arylmorpholinosuccinimdobicycloalkanecarboxamides III (R = Ph, 1-naphthyl; n = 1, 2, 7) or arylchloromorpholinocycloalkenecarboxamides IV (R = 1-naphthyl; n = 1, 2), resp. III were obtained by treating IV (R = Ph, 1-naphthyl, n = 1, 2, 7) with succinimide and EtN(CHMe2)2. IV were obtained from enamine V (n = 1, 2, 7) via acylation with RNCO and then chlorination with N-chlorosuccinimide. The structure of III (R = Ph, n = 7) was confirmed by x-ray crystal anal.

AN 1990:35776 CAPLUS

DN 112:35776

TI Functionalized chloro enamines in aminocyclopropane synthesis. I. Bicyclic and pentacyclic lactams from carbamoylated chloro enamines

AU Altmeier, Peter; Vilsmaier, Elmar; Wolmershaeuser, Gotthelf

CS Fachbereich Chem., Univ. Kaiserslautern, Kaiserslautern, D-6750, Fed. Rep. Ger.

SO Tetrahedron (1989), 45(10), 3189-202
CODEN: TETRAB; ISSN: 0040-4020

DT Journal

LA English

OS CASREACT 112:35776

10/27/04

IT **124570-78-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 124570-78-1 CAPLUS
CN 11H-Benzo[h]cyclopenta[1,3]cyclopropa[1,2-c]quinolin-11-one,
1,2,3,3a,3b,10-hexahydro-3b-(4-morpholinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI



AB A method of introducing the Cl2CHCH2 group at the 3-position of 2-quinolones is described. The method from 4-substituted 2-quinolones consists of 1) photoaddn. of Cl2C:CH2 to quinolones, e.g., I, 2) base treatment of the cross adduct, e.g., II, giving a bicyclobutane, e.g., III, and 3) chlorination and ring cleavage of the latter with HCl to give the final product, e.g., IV, with HCl. Treating IV with K2CO3 gave 75% dictamnine (V).
AN 1988:6240 CAPLUS
DN 108:6240
TI Cycloadditions in synthesis. XXXIV. A new method for introducing the 2,2-dichloroethyl group at the 3-position of the 2-quinoline system and the synthesis of dictamnine

10/27/04

AU Sato, Masayuki; Kawakami, Katsuhiro; Kaneko, Chikara
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Chemical & Pharmaceutical Bulletin (1987), 35(3), 1319-21
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 108:6240
IT **111736-14-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring cleavage-chlorination of)
RN 111736-14-2 CAPLUS
CN 2H-Cyclopropa[1,3]cyclopropa[1,2-c]quinolin-2-one, 7c-chloro-1,3,7b,7c-tetrahydro-7b-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI



AB The photochem. transformations of the title compds. I (R = H, Me) in protic and aprotic solvents is reported. Irradiation of I in both protic and aprotic solvents gave mixts. of 3 to 6 cyclic products. Shorter reaction times gave more products with higher yields of the primary products, cis- and trans-furoquinolinones II (R = H, Me). Longer reaction times gave fewer products with higher yields of secondary products, e.g., furoquinolinones III. Unusually large vicinal coupling consts. (18-19 Hz) in trans-II (R = H, Me) were shown by x-ray anal. on trans-II (R = Me) to be due mainly to the presence of unusually short C-C single bonds.
AN 1987:554263 CAPLUS
DN 107:154263
TI Photochemistry of the amide system: furancarboxanilide
AU Bates, Robert B.; Kane, Vinayak V.; Martin, Arnold R.; Mujumdar, Ratnakar B.; Ortega, Richard; Hatanaka, Yasumaru; Kanaoka, Yuichi; Sannohe, Kunio
CS Dep. Chem., Univ. Arizona, Tucson, AZ, 85721, USA
SO Journal of Organic Chemistry (1987), 52(14), 3178-80

CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 107:154263
IT **67735-55-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 67735-55-1 CAPLUS
CN 1H-Cyclopropa[c]quinoline-1-carboxaldehyde, 1a,2,3,7b-tetrahydro-3-methyl-2-oxo-, (1α,1aβ,7bβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI





AB Treatment of quinolinium salts I (R = Me, Et; R1 = H, Me, MeO) with dichlorocarbene gave the cyclopropaquinolines II (R2 = CCl3) in 72.4-89.7% yields. The dichlorocarbene was generated by treating CHCl3 with 50% NaOH containing PhN+Me3Cl-. Treatment of II (R = Me, Et; R1 = H; R2 = CCl3) (III) with LiAlH4 in THF gave the corresponding II (R2 = CHCl2), and alcoholysis of III in MeOH containing concentrated HCl gave the corresponding II (R2 = CO2Me).

Treatment of I (R = Me; R1 = 5-NO2, 6-NO2) with dichlorocarbene gave mixts. of II (R2 = H) and quinolinones IV.

AN 1979:557567 CAPLUS
DN 91:157567
TI Studies on nitrogen-containing heterocyclic compounds. XXXIX. 2 Step syntheses of cyclopropa[c]quinoline derivatives from quinoline derivatives, via quaternary quinolinium salts
AU Hamada, Yoshiki; Sugiura, Michihara
CS Fac. Pharm., Meijo Univ., Nagoya, 468, Japan
SO Yakugaku Zasshi (1979), 99(5), 493-9
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Japanese
OS CASREACT 91:157567
IT **71636-16-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 71636-16-3 CAPLUS
CN 2H-Cyclopropa[c]quinolin-2-one, 1,1-dichloro-1,1a,3,7b-tetrahydro-3-methyl-7-nitro- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI For diagram(s), see printed CA Issue.
AB The photocyclization products of acylanilides I, II, III, and IV depended on the nature of the heterocycle and on R. I (R = H) gave V under oxidative conditions and a mixture of VI and VII under nonoxidative conditions. The reactions involved the cyclization of the excited anilide to a common intermediate which gave the oxidized and nonoxidized products.
AN 1978:562745 CAPLUS
DN 89:162745
TI Photocyclization of heterocyclic acylanilides
AU Ninomiya, Ichiya; Kiguchi, Toshiko; Naito, Takeaki
CS Kobe Women's Coll. Pharm., Kobe, Japan
SO Heterocycles (1978), 9(8), 1023-9
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 89:162745
IT **67735-55-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 67735-55-1 CAPLUS
CN 1H-Cyclopropa[c]quinoline-1-carboxaldehyde, 1a,2,3,7b-tetrahydro-3-methyl-2-oxo-, (1α,1aβ,7bβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI



II



III



IV

AB The reaction of 2-chloroquinoline N-oxide (I) and NCCH2CO2Et in the presence of BzCl and Et3N gave II in 78% yield. The reaction of 2-phenylquinoline N-oxide gave III. The reaction of I and CH2(CN)2 gave IV.

AN 1978:152385 CAPLUS

DN 88:152385

TI A novel formation of cyclopropa[c]quinolines from some 2-substituted quinoline N-oxides

AU Saeki, Seitaro; Honda, Haruyoshi; Kaku, Yoshio; Funakoshi, Kazuhisa; Hamana, Masatomo

CS Fac. Pharm. Sci., Kyushu Univ., Fukuoka, Japan

SO Heterocycles (1977), 7(2), 801-6
CODEN: HTCYAM; ISSN: 0385-5414

DT Journal

LA English

IT **66223-44-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 66223-44-7 CAPLUS

CN 1H-Cyclopropa[c]quinoline-1-carboxylic acid, 1-cyano-1a,2,3,7b-tetrahydro-2-oxo-, ethyl ester, (1α,1aα,7bα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI For diagram(s), see printed CA Issue.
AB The title compns. are sedatives and muscle relaxants. Particularly claimed as active ingredients are 1a,7b-dihydro-3-methyl-1H-cyclopropa[c]quinolin-2-one and 1a,7b-dihydro-3-methyl-6-trifluoromethyl-1H-cyclopropa[c]quinolin - 2-one. These compds. are prepared from the corresponding quinoline by reaction with Me3S+(O) I- in the presence of a base. Thus, 11.85 g. of a 53.4% suspension of NaH in mineral oil was added by portions to a stirred suspension of 58 g. Me3S+(O) I- in Me2SO under N. After 1 hr., 10.6 g. N-methylcarbostyryl in Me2SO was added, the mixture stirred at ambient temperature for 30 min. and then at 60-70° for 2.5 hrs., let stand overnight, poured onto ice and the supernatant layer extracted with ether or CH2Cl2. The extract was dried, filtered, and concentrated, dissolved in MeCN and this solution was extracted with petroleum ether. The solution in MeCN was concentrated, dissolved in CH2Cl2, rinsed with H2O, dried, filtered, and concentrated to yield 1a,7b-dihydro-3-methyl-1H-cyclopropa[c]quinoline-2-one (I, R = H) (II), b0.005 98-104°. Similarly prepared was I (R = CF3). II at 50 mg./kg. in mice was 28.6% effective in suppressing anxiety.
AN 1967:520195 CAPLUS
DN 67:120195
TI 1a,7b-Dihydro-1H-cyclopropa[c]quinoline compositions
IN Loev, Bernard
PA Smith Kline and French Laboratories
SO Fr. M., 6 pp.
CODEN: FMXXAJ
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 4390		19661010		
PRAI US		19630429		

IT **1011-79-6**
RL: BIOL (Biological study)
(as muscle relaxant and sedative)
RN 1011-79-6 CAPLUS
CN 2H-Cyclopropa[c]quinolin-2-one, 1,1a,3,7b-tetrahydro-3-methyl- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
GI For diagram(s), see printed CA Issue.
AB I (X = H, R = Me) in dry Me2SO was treated with a 6-fold excess of dimethylsulfoxonium methylide (Corey and Chaykovsky, CA 57, 650h), the mixture hydrolyzed, and the oil distilled to give 43% II (X = H, R = Me), b0.005 100-4°, n24D 1.6100. Similarly prepared were II (X, R, m.p., and % yield given): 6-CF3, Me, 82.5-4°, 78; 6-CF3, Et, 60.5-2°, 56; 7-CF3, Me, 50°, 66. All compds. showed NMR spectral features attributed to the cyclopropane ring. Analogous reactions with N-methyl-4-quinolone and 1-methyl-2-quinoxalinone failed.
AN 1965:2986 CAPLUS
DN 62:2986
OREF 62:519c-e
TI 1-Methyl-3,4-methylene-3,4-dihydroquinolin-2-one(s). Derivatives of a new ring system, the 1H-cyclopropa[c]quinolines
AU Loev, B.; Kormendy, Minerva F.; Snader, K. M.
CS Smith Kline & French Labs., Philadelphia, PA
SO Chemistry & Industry (London, United Kingdom) (1964), (41), 1710
CODEN: CHINAG; ISSN: 0009-3068
DT Journal
LA Unavailable
IT **1023-31-0**, 2H-Cyclopropa[o]quinolin-2-one, 1,1a,3,7b-tetrahydro-3-methyl-6-(trifluoromethyl)-
(preparation of)
RN 1023-31-0 CAPLUS
CN 2H-Cyclopropa[c]quinolin-2-one, 1,1a,3,7b-tetrahydro-3-methyl-6-(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	58.00	213.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.40	-8.40

10/27/04

FILE 'STNGUIDE' ENTERED AT 18:08:04 ON 27 OCT 2004

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 22, 2004 (20041022/UP).

```
=> s l3
L5            5 L3

=> d abs bib fhitstr 1-5

L5   ANSWER 1 OF 5  USPATFULL on STN
AB     A pharmaceutical composition and method of modulating cholinergic
       function in a mammal comprising administration of a NRPA compound or a
       pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea
       agent or a pharmaceutically acceptable salt thereof; and a
       pharmaceutically acceptable carrier. The NRPA compound and the
       anti-emetic/anti-nausea agent are present in amounts that render the
       composition effective modulating cholinergic function or in the
       treatment of a diorder or condition selected from inflammatory bowel
       disease (including but not limited to ulcerative colitis, pyoderma
       gangrenosum and Crohn's disease), irritable bowel syndrome, spastic
       dystonia, chronic pain, acute pain, celiac sprue, pouchitis,
       vasoconstriction, anxiety, panic disorder, depression, bipolar disorder,
       autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS),
       cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac
       arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma,
       progressive supranuclear palsy, chemical dependencies and addictions
       (e.g., dependencies on, or addictions to nicotine (and/or tobacco
       products), alcohol, benzodiazepines, barbiturates, opioids or cocaine),
       headache, migraine, stroke, traumatic brain injury (TBI),
       obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea,
       tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct
       dementia, age-related cognitive decline, epilepsy, including petit mal
       absence epilepsy, senile dementia of the Alzheimer's type (AD),
       Parkinson's disease (PD), attention deficit hyperactivity disorder
       (ADHD) and Tourette's Syndrome. The method of using these compositions
       is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2004:216091  USPATFULL
TI     Pharmaceutical composition and method of modulating cholinergic function
       in a mammal
IN     Coe, Jotham W., Niantic, CT, UNITED STATES
       Sands, Steven B., Stonington, CT, UNITED STATES
PA     Pfizer Inc. (U.S. corporation)
PI     US 2004167200      A1   20040826
AI     US 2004-783790     A1   20040220 (10)
RLI    Continuation of Ser. No. US 2002-105606, filed on 25 Mar 2002, GRANTED,
       Pat. No. US 6672101
DT     Utility
FS     APPLICATION
LREP   PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
       10017-5612
CLMN   Number of Claims: 13
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT  483306-36-1
        (compns. containing nicotinic receptor partial agonist in combination with
       antiemetic for modulating cholinergic function)
RN   483306-36-1  USPATFULL
CN   2H-Cyclopropa[c]quinolin-2-one, 5-[[(6-ethyl-2-phenyl-3-
```

piperidinyl)amino]methyl]-1,1a,3,7b-tetrahydro-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 5 USPATFULL on STN

AB The present invention relates to inhibition of viruses, e.g., HIV using quinolones and compounds related to quinolones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:197413 USPATFULL

TI Quinolones with anti-HIV activity

IN He, Yun, San Diego, CA, UNITED STATES
Ellis, David Archer, San Diego, CA, UNITED STATES
Anaclerio, Beth Marie, San Diego, CA, UNITED STATES
Kuhen, Kelli L., Carlsbad, CA, UNITED STATES
Wu, Baogen, San Diego, CA, UNITED STATES
Jiang, Tao, San Diego, CA, UNITED STATES

PA IRM LLC, a Delaware LLC, Hamilton, HM LX, BERMUDA (U.S. corporation)

PI US 20041527l9 A1 20040805

AI US 2003-690738 A1 20031021 (10)

PRAI US 2002-420163P 20021021 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 2027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **685539-93-9P**
(quinolones with anti-HIV activity, and preparation thereof)

RN 685539-93-9 USPATFULL

CN 1aH-Cyclopropa[c]quinoline-1a-carboxylic acid, 6-chloro-7b-ethyl-1,2,3,7b-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 5 USPATFULL on STN

AB The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by helicobacter pylori, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:127710 USPATFULL

TI Benzoamide piperidine containing compounds and related compounds

IN O'Neill, Brian Thomas, Old Saybrook, CT, UNITED STATES
Nagel, Arthur Adam, Gales Ferry, CT, UNITED STATES
Humphrey, John Michael, Mystic, CT, UNITED STATES
Sobolov-Jaynes, Susan Beth, Ivoryton, CT, UNITED STATES
Chappie, Thomas Allen, Old Lyme, CT, UNITED STATES
Vincent, Lawrence Albert, Moosup, CT, UNITED STATES
Arnold, Eric Platt, Hebron, CT, UNITED STATES
Huang, Jianhua, Waterford, CT, UNITED STATES

PI US 2003087925 A1 20030508

AI US 2001-811218 A1 20010316 (9)

PRAI US 2000-195922P 20000410 (60)
US 2000-212922P 20000620 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612

CLMN Number of Claims: 79

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8586

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **368832-27-3P**
(drug candidate; synthesis of benzoamide piperidine containing compds. as substance P antagonists)

RN 368832-27-3 USPATFULL

CN 2H-Cyclopropa[c]quinolin-2-one, 1,1a,3,7b-tetrahydro-6-methoxy-3-methyl-5-[[[(2R,3R)-2-phenyl-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 4 OF 5 USPATFULL on STN

AB A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:11188 USPATFULL
TI Pharmaceutical composition and method of modulating cholinergic function in a mammal
IN Coe, Jotham W., Niantic, CT, UNITED STATES
Sands, Steven B., Stonington, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2003008892 A1 20030109
AI US 2002-105605 A1 20020325 (10)
PRAI US 2001-303957P 20010709 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1977

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **483306-36-1**
(compns. containing nicotinic receptor partial agonist in combination with antiemetic for modulating cholinergic function)

RN 483306-36-1 USPATFULL

CN 2H-Cyclopropa[c]quinolin-2-one, 5-[[(6-ethyl-2-phenyl-3-piperidinyl)amino]methyl]-1,1a,3,7b-tetrahydro-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 5 USPATFULL on STN

AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a 5HT1D receptor antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT.sub.1D receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:92687 USPATFULL

TI Combination treatment for depression and anxiety

IN Sobolov-Jaynes, Susan Beth, Ivoryton, CT, UNITED STATES
Schmidt, Christopher Joseph, Old Lyme, CT, UNITED STATES

PI US 2002049211 A1 20020425
AI US 2001-867357 A1 20010529 (9)
PRAI US 2000-230257P 20000906 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4999

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **368832-27-3**
(combination, for treating depression and anxiety, containing a 5HT1D receptor antagonist and a CNS penetrant NK-1 receptor antagonist)

RN 368832-27-3 USPATFULL

CN 2H-Cyclopropa[c]quinolin-2-one, 1,1a,3,7b-tetrahydro-6-methoxy-3-methyl-5-[[[(2R,3R)-2-phenyl-3-piperidinyl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10/27/04

=>